|
ChemicalBook Optimization Suppliers |
|
| | (R)-α-[[(E)-3-(3,4-ジヒドロキシフェニル)-1-オキソ-2-プロペニル]オキシ]-3,4-ジヒドロキシベンゼンプロパン酸 製品概要 |
| | (R)-α-[[(E)-3-(3,4-ジヒドロキシフェニル)-1-オキソ-2-プロペニル]オキシ]-3,4-ジヒドロキシベンゼンプロパン酸 物理性質 |
| 融点 | 171-175 °C (lit.) | | 比旋光度 | +102～+110°(D/20℃)(c=0.2,C2H5OH) | | 沸点 | 694.7±55.0 °C(Predicted) | | 比重(密度) | 1.33 | | 貯蔵温度 | 2-8°C | | 溶解性 | Soluble in ethanol, DMSO or dimethyl formamide to approximately 25 mg/mL. | | 酸解離定数(Pka) | 2.78±0.10(Predicted) | | 外見 | powder | | 色 | white to faintly beige | | BRN | 2227587 | | 安定性： | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month. | | InChI | InChI=1/C18H16O8/c19-12-4-1-10(7-14(12)21)3-6-17(23)26-16(18(24)25)9-11-2-5-13(20)15(22)8-11/h1-8,16,19-22H,9H2,(H,24,25)/b6-3+/t16-/s3 | | InChIKey | DOUMFZQKYFQNTF-WUTVXBCWSA-N | | SMILES | C(C1C=CC(O)=C(O)C=1)[C@H](C(=O)O)OC(=O)/C=C/C1C=CC(O)=C(O)C=1 |&1:9,r| | | LogP | 0.871 (est) | | CAS データベース | 20283-92-5(CAS DataBase Reference) |
| 主な危険性 | T | | Rフレーズ | 25 | | Sフレーズ | 45 | | WGK Germany | 3 | | RTECS 番号 | GD8990000 | | F | 10-23 | | HSコード | 29189900 |
| | (R)-α-[[(E)-3-(3,4-ジヒドロキシフェニル)-1-オキソ-2-プロペニル]オキシ]-3,4-ジヒドロキシベンゼンプロパン酸 Usage And Synthesis |
| 外観 | 白色～微黄色の結晶又は結晶性の粉末 | | 定義 | 本品は、コウスイハッカ Melissa officinalis 又はマンネンロウ Rosmarinus officinalis から得られる酸であり、次の化学式で表される。 | | 溶解性 | エタノールに溶ける。 | | 用途 | 日本薬局方収載「柴朴湯エキス」、「半夏厚朴湯エキス」に含まれるソヨウの確認試験用、ロスマリン酸の定量法用 | | 化粧品の成分用途 | 酸化防止剤 | | 使用上の注意 | アルゴン封入 | | 説明 | Rosmarinic acid (20283-92-5) displays radical scavenging1, anti-inflammatory2 and amyloid-β aggregation inhibition activities.3 Rosmarinic acid has also been shown to act as an agonist at GPR35.4 | | 化学的特性 | White to off-white powder | | 使用 | Rosmarinic Acid is a phenolic compound with antioxidant and anti-inflammatory activity. Rosmarinic Acid has been shown to inhibit againts peroxidative damage to biomembranes. Rosmarinic Acid also supp
resses endotoxin-induced activation of complement and concomitant prostacyclin biosynthesis. | | 使用 | An activator of GPR35. | | 使用 | Rosmarinic acid is a naturally-occurring phenolic compound with antioxidant and anti-inflammatory properties. This compound inhibits lipid peroxidation of rat liver microsomes by 90% at a concentration of 25 μg/ml. Rosmarinic acid suppresses endotoxin-induced activation of complement and concomitant formation of prostacyclin. Formation of 5-HETE and LTB4 from human PMNL is inhibited by rosmarinic acid at concentrations of 10-5 to 10-3 M. | | 定義 | ChEBI: (R)-rosmarinic acid is a stereoisomer of rosmarinic acid having (R)-configuration. It has a role as a plant metabolite and a geroprotector. It is a conjugate acid of a (R)-rosmarinate. It is an enantiomer of a (S)-rosmarinic acid. | | 一般的な説明 | Rosmarinic acid is a bioactive plant phenolic compound with antioxidant and anti-inflammatory effects. | | 生物活性 | Anti-inflammatory, cytostatic and antiviral. | | Biochem/physiol Actions | Rosmarinic acid has shown to contain antioxidant, anti-inflammatory and antimicrobial activities. Possesses promising physiological actions related to cognitive performance, Alzheimer′s disease prevention, kideney disease treatment, cardioprotection and cancer chemoprevention. | | Mode of action | Rosmarinic acid (RA), a water-soluble polyphenolic compound with antioxidant and anti-inflammatory properties. Inhibits several complement-dependent inflammatory processes via inhibition of the C5 convertase. Anticarcinogenic. Inhibitor of lipid peroxidation, TCR-induced T cell activation and proliferation.? | | 参考文献 | 1) Miliauskas et al. (2005), Identification of radical scavenging compounds in Rhaponticum carthamoides by means of LC-DAD-SPE-NMR; J. Nat. Prod., 68 168
2) Sahu et al. (1999), Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b; Biochem. Pharmacol, 57 1439
3) Ono et al. (2012), Phenolic compounds prevented amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding; J. Biol. Chem., 287 14631
4) Deng et al. (2012), Multiple tyrosine metabolites are GPR35 agonists; Sci. Rep., 2 373 |
|